skip to Main Content

Clinical Trials

Istari Oncology is committed to the successful clinical development and registration of PVSRIPO and other technologies for the treatment of cancer.


PVSRIPO has been granted Breakthrough Therapy and Orphan Drug Designation by FDA in recurrent glioblastoma (rGBM).

PVSRIPO has been granted Orphan Drug Designation by FDA in advanced melanoma.

Current Clinical Trials





We are currently evaluating D2C7 in a dose escalation Phase 1 study, which began in 2014. The study is scheduled to end in 2020. A combination trial, D2C7 plus atezolizumab, is currently enrolling.

Current Clinical Trials

Back To Top
×Close search